<DOC>
	<DOCNO>NCT01852799</DOCNO>
	<brief_summary>This multicentre ; single arm study subject newly diagnose multiple myeloma . The primary objective study assess effect bortezomib combination therapy ( PAD regimen ) follow ASCT bone metabolites patient newly diagnose multiple myeloma , measure ELISA methodology previously describe analyze change biochemical bone marker compare baseline value : bone formation marker- bone alkaline phosphatase ( bALP ) osteoblast inhibitor- Dickkopf-1 ( DKK-1） . The secondary objective study : 1 . Subgroup analysis change baseline biochemical bone marker base whether Bisphosphonate use . 2 . Assessment bone marker parameter : bone formation marker -carboxy terminal propeptide type I procollagen ( PICP ) ; bone resorption marker -carboxy terminal telopeptide region type I collagen ( ICTP ) ; osteoclast stimulators -osteoprotegerin ( OPG ) , soluble receptor activator nuclear factor kappaB ligand ( sRANKL ) ; 3 . To observe effect bortezomib bone mineral density ( BMD ) measure repeated quantitative CT-scan ; 4 . The evaluation Skeletal related event ( SRE ) appearance new bone lesion ; 5 . To determine progression free survival ( PFS ) , 1 year survival , overall survival safety profile follow treatment PAD ASCT first-line therapy .</brief_summary>
	<brief_title>A Study PAD Followed Autologous Stem Cell Transplantation ( ASCT ) Treat Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>After provide write informed consent , subject evaluate eligibility 14-day screening period . Eligible subject receive 4 cycle PAD treatment prior ASCT . Bisphosphonate therapy administer medically indicate accord local practice . After end treatment phase , 18 month follow-up period every patient visit 4 , 6 , 12 18 month end treatment phase . In case disease progress complete 18 month follow-up subject start alternative MM treatment , study assessment stop , except survival follow-up collect every 6 month either telephone call visit study site . The follow-up survival continue subject last subject complete follow-up . One interim analysis efficacy safety perform subject achieve end treatment . Safety assess monitor adverse event , physical examination , vital sign measurement clinical laboratory test .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>1 . Man woman age 18 65 year old ; 2 . Subjects newly diagnose MM patient schedule investigator treat vincristine , adriamycin dexamethasone standard therapy . Stage II/III ( accord Durie Salmon criterion ) skeletal involvement , bone pain , bone lytic lesion , diffuse osteoporosis pathologic fracture ; 3 . Life expectancy &gt; 3 month ; 4 . Patient measurable disease capture response , define one following ; Serum Mprotein level &gt; 10.0 g/L measure serum protein electrophoresis immunoglobulin electrophoresis ; Urinary Mprotein excretion &gt; 1 g/24 hour ; Bone marrow plasmacytosis &gt; 30 % bone marrow aspirate and/or biopsy ; Serum free light chain ( Freelite test ) &gt; 2 X upper limit normal ( ULN ) , absence renal failure . 5 . Performance status ( PS ) ECOG ≤2.0 , unless PS 34 base solely bone pain ; 6 . Patients must Platelets count≥50×109 cell /L ; Absolute neutrophil count ( ANC ) ≥0.75×109 cell /L ; 7 . Patients must adequate hepatic function define Alanine transaminase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) ; Aspartate transaminase ( AST ) ≤2.5×ULN ; Total bilirubin ≤2×ULN ; 8 . Patients must adequate renal function define creatinine clearance &gt; 30 ml /min ; 9 . Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . 1 . Nonsecretory MM , unless patient measurable lesion compute tomography ( CT ) , magnetic resonance imaging ( MRI ) and/or positron emission tomography ( PET ) ; 2 . Peripheral neuropathy neuropathy pain grade 2 high define National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 3 ; 3 . Uncontrolled severe cardiovascular disease , include myocardial infarction ( MI ) within 6 month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis ; 4 . History allergy reaction attributable compound contain boron mannitol ; 5 . Any serious , active disease psychiatric illness could potentially interfere completion treatment accord protocol investigator 's decision ; 6 . Concurrent treatment another investigational agent ; 7 . Female subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>PAD</keyword>
	<keyword>ASCT</keyword>
	<keyword>Bone metabolite</keyword>
	<keyword>Bone marker</keyword>
</DOC>